Four years after winning an FDA approval for Koselugo to treat children with the rare disorder neurofibromatosis type 1 (NF1) ...

Other researchers have also been studying mixing vaccine types to fight COVID-19. A Spanish study recently reported that people who initially received the AstraZeneca vaccine experienced a massive ...

finds bombshell new study into the origin of the global pandemic "This has led to a decline in demand for Vaxzevria, which is ...

Six months after Amgen and AstraZeneca reported promising results for Tezspire (t | A phase 3 study has shown that ...

The safety profile of Koselugo in this study was consistent with that observed in clinical trials among children and adolescents. No new safety signals were identified. Alexion, AstraZeneca Rare ...

A new SERD molecular entity, camizestrant, is under clinical development by biopharmaceutical company AstraZeneca and is currently in a Phase III study. The drug candidate is administered orally ...

British drug maker AstraZeneca Plc (AZN.L, AZN) announced Tuesday positive data from global KOMET Phase III trial, in which Koselugo ...

The study, published in Nature Communications ... the wide uptake of future COVID-19 vaccination programs. In July, AstraZeneca declared a worldwide cessation of its COVID-19 vaccine, Vaxzevria ...

Giving people the tools to do their job more effectively has boosted productivity at AstraZeneca ... the benefits of this evolution in a case study video produced by Veeva. She said: “We ...

The Pfizer and AstraZeneca coronavirus vaccines are highly effective against the variant identified in India after two doses, a study has found. Two jabs of either vaccine give a similar level of ...

AstraZeneca may be emphasizing the potential ... This follows an early-stage study that demonstrated AZD5004's “favorable tolerability and safety profile," according to the company.

AstraZeneca Plc said its experimental obesity ... an average of 5.8% of their body weight over four weeks in an early study, the UK pharma company reported at the ObesityWeek conference in San ...